Merck Manual

Please confirm that you are a health care professional

Loading

Ankylosing Spondylitis

By

Apostolos Kontzias

, MD, Stony Brook University School of Medicine

Last full review/revision May 2020| Content last modified May 2020
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Ankylosing spondylitis is the prototypical spondyloarthropathy and a systemic disorder characterized by inflammation of the axial skeleton, large peripheral joints, and digits; nocturnal back pain; back stiffness; accentuated kyphosis; constitutional symptoms; aortitis; cardiac conduction abnormalities; and anterior uveitis. Diagnosis requires showing sacroiliitis on x-ray. Treatment is with nonsteroidal anti-inflammatory drugs and/or tumor necrosis factor antagonists or interleukin-17 (IL-17) antagonists and physical measures that maintain joint flexibility.

Ankylosing spondylitis is 3 times more frequent in men than in women and begins most often between ages 20 and 40. It is 10 to 20 times more common among 1st-degree relatives of patients with ankylosing spondylitis than in the general population. The human leukocyte antigen B27 (HLA-B27) allele is present in 90% of white patients with ankylosing spondylitis, but it is also present in up to 10% of the general population depending on ethnicity. The risk of ankylosing spondylitis in 1st-degree relatives with the HLA-B27 allele is about 20%. Increased prevalence of HLA-B27 in whites or HLA-B7 in blacks supports a genetic predisposition. However, the concordance rate in identical twins is only about 50%, suggesting that environmental factors contribute. The pathophysiology probably involves immune-mediated inflammation.

Classification

Most patients have predominantly axial involvement (called axial ankylosing spondylitis). Some have predominately peripheral involvement. Among those with axial involvement, some have no evidence of sacroiliitis on plain x-rays. Thus, some experts have classified ankylosing spondylitis as follows:

  • Axial ankylosing spondylitis: Has predominantly axial involvement and x-ray findings typical of sacroiliitis

  • Nonradiographic ankylosing spondylitis: Clinically similar to axial ankylosing spondylitis but without x-ray findings typical of sacroiliitis

  • Peripheral ankylosing spondylitis: Ankylosing spondylitis with predominantly peripheral involvement

Symptoms and Signs

The most frequent manifestation of ankylosing spondylitis is inflammatory back pain, but disease can begin in peripheral joints, especially in children and women, and rarely with acute iridocyclitis (iritis or anterior uveitis). Other early symptoms and signs are diminished chest expansion from diffuse costovertebral involvement, low-grade fever, fatigue, anorexia, weight loss, and anemia.

Back pain—often nocturnal and of varying intensity—eventually becomes recurrent. Morning stiffness, typically relieved by activity, and paraspinal muscle spasm develop. A flexed or bent-over posture eases back pain and paraspinal muscle spasm; thus, kyphosis is common in untreated patients. Severe hip arthritis can eventually develop. In late stages, the patient has accentuated kyphosis, loss of lumbar lordosis, and fixed bent-forward posturing, with compromised pulmonary function and inability to lie flat. There may be peripheral potentially deforming joint involvement, sometimes involving the digits (dactylitis). Achilles and patellar tendinitis can occur.

Systemic manifestations of ankylosing spondylitis occur in one third of patients. Recurrent, acute anterior uveitis is common and usually responds to local therapy; less commonly it becomes protracted and severe enough to impair vision. Neurologic signs occasionally result from compression radiculitis or sciatica, vertebral fracture or subluxation, or cauda equina syndrome. Cardiovascular manifestations can include aortic insufficiency, aortitis, angina, pericarditis, and cardiac conduction abnormalities (which may be asymptomatic). Dyspnea, cough, or hemoptysis can rarely result from nontuberculous fibrosis or cavitation of an upper lobe of the lung; cavitary lesions can become secondarily infected with Aspergillus. Rarely, ankylosing spondylitis results in secondary amyloidosis. Subcutaneous nodules do not develop.

Diagnosis

  • Lumbosacral spine and sacroiliac joint radiography

  • Blood tests (erythrocyte sedimentation rate [ESR], C-reactive protein, human leukocyte antigen B27 [HLA-B27], and complete blood count) or explicit clinical criteria (Assessment of SpondyloArthritis international Society criteria)

  • Pelvic MRI in select patients

Ankylosing spondylitis should be suspected in patients, particularly young men, with nocturnal back pain and kyphosis, diminished chest expansion, Achilles or patellar tendinitis, or unexplained anterior uveitis. A 1st-degree relative with ankylosing spondylitis should heighten suspicion.

Patients should generally be tested with ESR, HLA-B27, C-reactive protein, and complete blood count. Rheumatoid factor (RF) and antinuclear antibodies are needed only if peripheral arthritis suggests other diagnoses. The HLA-B27 allele is present in 90% of white patients with ankylosing spondylitis, but it is also present in up to 10% of the general population depending on ethnicity. No laboratory test is diagnostic, but results can increase suspicion for the disorder or rule out other disorders that can simulate ankylosing spondylitis. If, after these tests, ankylosing spondylitis is still suspected, patients should undergo x-ray or MRI of the lumbosacral spine and sacroiliac joints; demonstration of sacroiliitis on x-ray strongly supports the diagnosis.

Some patients should undergo pelvic MRI to look for sacroiliitis that is not seen on x-rays. In these patients, MRI shows osteitis or early erosions.

Although there are several existing diagnostic criteria for patients with suspected ankylosing spondylitis, the Assessment of SpondyloArthritis international Society (ASAS) criteria (1, 2) are most often applied. They are useful in diagnosing patients earlier in the disease process, particularly those without spondyloarthritis on imaging. The ASAS criteria for axial spondyloarthritis are applied to patients who have had back pain for > 3 months and who are < 45 years of age at onset.

Diagnosis can be done using ASAS imaging or clinical criteria. To fulfill the imaging criteria, patients must have radiographic or MRI evidence of sacroiliitis plus at least 1 spondyloarthritis feature. To fulfill the clinical criteria, patients must have HLA-B27 plus at least 2 separate spondyloarthritis features. ASAS spondyloarthritis features include the following:

  • Dactylitis

  • Enthesitis of the heel

  • Family history of spondyloarthritis

  • History of inflammatory back pain

  • Arthritis

  • Presence of HLA-B27

  • Elevated C-reactive protein

  • Good response to nonsteroidal anti-inflammatory drugs

Historical features that distinguish inflammatory back pain from noninflammatory back pain include onset at 40 years, gradual onset, morning stiffness, improvement with activity, and duration 3 months before seeking medical attention.

ESR and other acute-phase reactants (eg, C-reactive protein) are inconsistently elevated in patients with active ankylosing spondylitis. Tests for RF and antinuclear antibodies are negative. The HLA-B27 genetic marker is not usually helpful because positive and negative predictive values are low.

The earliest x-ray abnormalities are pseudowidening caused by subchondral erosions, followed by sclerosis or later narrowing and eventually fusion in the sacroiliac joints. Changes are symmetric. Early changes in the spine are upper lumbar vertebral squaring with sclerosis at the corners; spotty ligamentous calcification; and one or two evolving syndesmophytes. Late changes result in a “bamboo spine” appearance, resulting from prominent syndesmophytes, diffuse paraspinal ligamentous calcification, and osteoporosis; these changes develop in some patients on average over 10 years.

Changes typical of ankylosing spondylitis may not become visible on plain x-rays for years. MRI shows changes earlier, but there is no consensus regarding its role in routine diagnosis given the lack of prospective, validated data in regard to its diagnostic utility. Pelvic MRI should be done if the index of suspicion of spondyloarthritis is high or if there is a need to rule out other causes of the patient's symptoms.

A herniated intervertebral disk can cause back pain and radiculopathy similar to ankylosing spondylitis, but the pain is limited to the spine and nerve roots, usually causes more sudden symptoms, and causes no systemic manifestations or laboratory test abnormalities. If necessary, CT or MRI can differentiate it from ankylosing spondylitis. Involvement of a single sacroiliac joint suggests a different spondyloarthropathy, possibly infection. Tuberculous spondylitis can simulate ankylosing spondylitis (see tuberculosis of bones and joints).

Diffuse idiopathic skeletal hyperostosis (DISH) occurs primarily in men > 50 years and may resemble ankylosing spondylitis clinically and on x-ray. Patients uncommonly have spinal pain, stiffness, and insidious loss of motion. X-ray findings in DISH include large ossifications anterior to spinal ligaments (the calcification appears as if someone poured candle wax in front and on the sides of the vertebrae), bridging several vertebrae and usually starting at the lower thoracic spine, eventually affecting the cervical and lumbar spine. There is often subperiosteal bone growth along the pelvic brim and at insertion of tendons (such as the Achilles tendon insertion). However, the anterior spinal ligament is intact and frequently bulging, and sacroiliac and spinal apophyseal joints are not eroded. Additional differentiating features are stiffness that is usually not markedly accentuated in the morning and a normal erythrocyte sedimentation rate (ESR).

Diagnosis references

  • 1. Sepriano A, Landewé R, van der Heijde D, et al: Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: A final analysis. Ann Rheum Dis 75(6):1034–1042, 2016. doi: 10.1136/annrheumdis-2015-208730.

  • 2. Sepriano A, Rubio R, Ramiro S, et al: Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: A systematic literature review and meta-analysis. Ann Rheum Dis 76(5):886–890, 2017. doi: 10.1136/annrheumdis-2016-210747. Epub 2017 Feb 8.

Prognosis

Ankylosing spondylitis is characterized by mild or moderate flares of active inflammation alternating with periods of little or no inflammation. Proper treatment in most patients results in minimal or no disability and in a full, productive life despite back stiffness. Occasionally, the course is severe and progressive, resulting in pronounced incapacitating deformities.

Treatment

  • Nonsteroidal anti-inflammatory drugs (NSAIDs)

  • Sulfasalazine, methotrexate, tumor necrosis factor (TNF)-alpha antagonists, or interleukin-17 (IL-17) antagonists (eg, secukinumab, ixekizumab)

  • Exercises and supportive measures

The goals of treatment of ankylosing spondylitis are relieving pain, maintaining joint range of motion, and preventing end-organ damage. Because the condition may cause lung fibrosis, cigarette smoking is discouraged. (See also the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) 2016 update of the management recommendations for axial spondyloarthritis.)

NSAIDs reduce pain and suppress joint inflammation and muscle spasm, thereby increasing range of motion, which facilitates exercise and prevents contractures. Most NSAIDs work in ankylosing spondylitis, and tolerance and toxicity dictate drug choice. The daily dose of NSAIDs should be as low as possible, but maximum doses may be needed with active disease. Drug withdrawal should be attempted only slowly, after systemic and joint signs of active disease have been suppressed for several months.

Sulfasalazine may help reduce peripheral joint symptoms and laboratory markers of inflammation in some patients. Dosage should be started at 500 mg/day and increased by 500 mg/day at 1-week intervals to 1 to 1.5 g 2 times a day maintenance; because acute neutropenia can occur, cell counts must be monitored when initiating therapy or increasing drug dose. Peripheral joint symptoms may also abate with methotrexate, but spinal symptoms are usually not reduced.

TNF-alpha antagonists (eg, etanercept, infliximab, adalimumab, certolizumab, golimumab) are often strikingly effective treatments for inflammatory back pain.

Secukinumab, an IL-17 antagonist, has also been effective in reducing inflammation and joint symptoms. Secukinumab can be given at a dosage of 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without the loading (weekly) doses, secukinumab is 150 mg subcutaneously every 4 weeks. Adverse effects include urticaria, upper respiratory infections, fungal infections due to Candida, diarrhea, herpes zoster, and inflammatory bowel disease.

Ixekizumab, another IL-17 inhibitor, can be given for active ankylosing spondylitis as an injection of 80 mg/mL for adult patients every 4 weeks after a loading dose of 160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12. It can be administered as monotherapy or in combination with conventional DMARDs or NSAIDs.

Systemic corticosteroids, immunosuppressants, and most disease-modifying antirheumatic drugs (DMARDs) have no proven benefit in axial spondyloarthritides and should generally not be used.

For proper posture and joint motion, daily exercise and other supportive measures (eg, postural training, therapeutic exercise) are vital to strengthen muscle groups that oppose the direction of potential deformities (ie, the extensor rather than flexor muscles). Reading while lying prone and pushing up on the elbows or pillows and thus extending the back may help keep the back flexible. Because chest wall motion can be restricted, which impairs lung function, cigarette smoking, which also impairs lung function, is strongly discouraged.

Intra-articular depot corticosteroids may be beneficial, particularly when one or two peripheral joints are more severely inflamed than others, thereby compromising exercise and rehabilitation. They may also help if systemic drugs are ineffective. Imaging-guided corticosteroid injections into the sacroiliac joints may occasionally help severe sacroiliitis.

For acute uveitis, topical corticosteroids and mydriatics are usually adequate.

If severe hip arthritis develops, total hip arthroplasty may lessen pain and improve flexibility dramatically.

Key Points

  • Ankylosing spondylitis is a systemic disorder that affects axial and peripheral joints and can cause constitutional symptoms, cardiac symptoms, and anterior uveitis.

  • Initial manifestation is usually inflammatory back pain and stiffness sometimes along with peripheral joint symptoms and/or anterior uveitis.

  • Diagnose based on the results of lumbosacral spine imaging, sacroiliac joint imaging, pelvic MRI, blood tests (erythrocyte sedimentation rate, C-reactive protein, human leukocyte antigen B27 [HLA-B27], and complete blood count), and/or explicit clinical criteria.

  • Use nonsteroidal anti-inflammatory drugs to help reduce symptom severity and improve function.

  • Use sulfasalazine, methotrexate, tumor necrosis factor (TNF)-alpha antagonists, or interleukin-17 (IL-17) antagonists to relieve joint symptoms.

More Information

Drugs Mentioned In This Article

Drug Name Select Trade
AZULFIDINE
OTREXUP
COSENTYX
ENBREL
REMICADE
HUMIRA
Ixekizumab
SIMPONI
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
How to Examine the Foot
Video
How to Examine the Foot
3D Models
View All
Vertebral Column and Spinal Cord
3D Model
Vertebral Column and Spinal Cord

SOCIAL MEDIA

TOP